Moreover, although new therapeutic implementations targeting aberrant TP53 based on synthetic lethality, gene editing, and siRNA silencing are still at the preliminary stages [40], redefining the current IHC model through adequate recognition of the p53 low-level phenotype as aberrant might also be helpful in the future to correctly assign target treatment to CIN GEA patients. This evidence concerns the gene TP53 and cervical squamous intraepithelial neoplasia.